Neu­ro­crine's $50M bet on Idor­sia drug flames out in sec­ond PhII

The drug that Neu­ro­crine Bio­sciences li­censed from Idor­sia for $50 mil­lion has flunked a sec­ond Phase II study, fail­ing to help pe­di­atric pa­tients with a rare type of epilep­sy.

Just a few months ago, Neu­ro­crine re­vealed that NBI-827104, a cal­ci­um chan­nel block­er, did not meet the end­point in a sep­a­rate mid-stage study for es­sen­tial tremor.

“We think ex­pec­ta­tions for the tri­al were low,” wrote Cowen an­a­lyst Phil Nadeau. And he added that the neg­a­tive read­out may put the pro­gram to bed: “Af­ter two failed stud­ies, we sus­pect there is no path for­ward for ‘104.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER